Banner
Workflow

The trouble with a Nobel for mRNA COVID vaccines

Contact Counsellor

The trouble with a Nobel for mRNA COVID vaccines

  • The 2023 Nobel Prize for Physiology or Medicine was recently awarded to Katalin Kariko and Drew Weissman.
  • They won the award for developing the mRNA vaccine technology that became the foundation for history’s fastest vaccine development programme during the COVID19 pandemic.

mRNA Vaccines

  • Such vaccines make use of the messenger RNA molecules that tell the body’s cells what proteins to build.
  • Here, the mRNA is coded to tell the cells to recreate the spike protein of the coronavirus SARS-CoV-2, which causes Covid-19.
  • A coronavirus vaccine based on mRNA, once injected into the body, will instruct the body’s cells to create copies of the spike protein.
  • In turn, this is expected to prompt the immune cells to create antibodies to fight it.
  • These antibodies will remain in the blood and fight the real virus if and when it infects the human body.

Nobel Prize 2023

  • It acknowledges work that has created benefits “for all mankind”.
  • However, if we had to be stricter about holding scientific accomplishments up to this standard, the subset of mRNA vaccines used during the COVID-19 pandemic may not meet it.
  • Yet, they deserved to win the prize for their scientific accomplishments.
  • Instead, their triumph tells us what “for all mankind” should really mean.

At the expense of public funds

  • A significant portion of the foundational research behind the development of new drugs and vaccines is conducted using government funding.
    • It involves the identification of potential biomolecular targets within the body that could be targeted by a drug to treat a specific disease.
    • This is followed by the search for suitable chemical candidates.
  • The estimated cost and time for this phase are $1 billion to $2.5 billion and several decades respectively.
  • Companies subsequently commoditise and commercialise these entities, raking in millions in profits.
    • This is typically at the expense of the same people whose taxes funded the fundamental research.
  • The current drug and vaccine development model encourages innovation and the resulting competition helps reduce prices.
  • However, one cannot deny the ‘double-spend’ it imposes on consumers including governments.
  • Additionally, it also encourages a profit-driven mindset among the companies involved in the development and production of these products.

Moderna and Pfizer Vaccines

  • After Moderna and Pfizer began producing their mRNA COVID-19 vaccines, they were mired in North American and European countries’ determination to make sure they had ample for themselves.
  • Their use in other countries (including India) was also complicated by protracted negotiations over pricing and liability.

On COVAX

  • COVAX is one of three pillars of the Access to COVID-19 Tools (ACT) Accelerator.
  • It was launched in April 2020 by the World Health Organization (WHO), the European Commission and France in response to the Covid-19 pandemic.
  • It is an effort to ensure that people in all corners of the world will get access to Covid-19 vaccines once they are available, regardless of their wealth.
  • However, this programme fell far short of its targets.
  • India, Russia, and China exported billions of doses of their vaccines, but their efforts were beset by concerns.
  • It included concerns like overestimated manufacturing capacity (in India’s case) and quality (in Russia’s and China’s case).
  • There were reports of several countries in Africa having to throw away lakhs of vaccine doses because they had been exported too close to their expiry dates.

On Corbevax

  • A counterexample to the path that Dr. Kariko followed is Corbevax.
  • Baylor College of Medicine, Houston, and the Texas Children’s Hospital Centre for Vaccine Development developed this protein subunit vaccine.
  • They licensed it to India’s Biological E for manufacturing but did not patent it.
  • It helped in the development and distribution of a low cost COVID19 vaccine to people of the world without patent limitation.

Conclusion

  • We cannot blame our scientists for trying to profit from their work.
  • The mRNA vaccine could have benefited everyone during the pandemic, but it did not.
  • So, history should remember what actually happened during the pandemic and what the 2023 Medicine Nobel claims happened differently.

Categories